September 29, 2010


Legendary Singer to Raise Awareness of Knee Osteoarthritis

Parsippany, NJ- September 29, 2010 – Grammy Award winner Gloria Gaynor—whose hit songs have captivated the public for over 35 years—will appear at AARP’S Orlando@50+ National Event & Expo to raise awareness of knee osteoarthritis (OA), including her own experience with this potentially debilitating condition. This high profile event, with an estimated attendance of 25,000, will take place September 30-October 2 at the Orange County Convention Center in Orlando, FL.

Ms. Gaynor—who has struggled with osteoarthritis (OA) knee pain since 1984—is the national spokesperson for EUFLEXXA® (1% sodium hyaluronate), a treatment for the pain of knee osteoarthritis. Visit to learn more about Gloria’s story. Her AARP appearance will be the latest in a series of events designed to highlight the widespread problem of knee osteoarthritis, and the medical options available to treat the pain it causes.

Ms. Gaynor will visit the EUFLEXXA booth [#2471] on Thursday, September 30, to have her photo taken with consumers. “It means so much to raise awareness of knee osteoarthritis and treatments that can help reduce the pain associated with this condition,” says Ms. Gaynor. “I am thrilled to announce that EUFLEXXA will provide free knee screenings and physician consultations for AARP attendees who may be wondering about their knee pain.” Ms. Gaynor will also be performing at the World’s Greatest Dance Party on Friday, October 1, along with Los Lobos and World Classic Rockers. Ms. Gaynor, who says she remains a “survivor,” was diagnosed with OA of the knee over 25 years ago. She tried numerous treatment options to manage the pain including exercise, various non-drug therapies, simple pain relievers and other forms of hyaluronic acid (HA) therapy. Ms Gaynor found success with EUFLEXXA.

Ms. Gaynor was treated with EUFLEXXA in 2009 and has joined the many knee osteoarthritis sufferers who are highly satisfied with EUFLEXXA.

Ms. Gaynor experienced her first major success in 1975 with the classic song, “Never Can Say Goodbye.” She went on to record a string of major hits, most notably “I Will Survive,” a Grammy Award winning song that has become an anthem for women around the world. Ms. Gaynor, also known as the Queen of Disco, celebrated the song’s 30th anniversary in 2009. She is currently traveling the world performing, and most recently appeared on “Last Comic Standing” and “The Tonight Show with Jay Leno.”


EUFLEXXA® (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.


You should not receive this product if you have had any previous allergic reaction to EUFLEXXA® or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site. EUFLEXXA® is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA® have not been established. The safety and effectiveness of EUFLEXXA® have not been shown in people under 18 years of age.

Side effects sometimes seen when EUFLEXXA® is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long. Visit for full prescribing information.

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience. ORTIKOS is a trademark of Sun Pharma Global FZE.

©2008-2020 Ferring Pharmaceuticals.  US-CORP-2000062